1. Gal-2 Increases H3K4me3 and H3K9ac in Trophoblasts and Preeclampsia
   Laura Hahn et al, 2022, Biomolecules CrossRef
2. Good or bad: Paradox of plasminogen activator inhibitor 1 (PAI-1) in digestive system tumors
   Bofang Wang et al, 2023, Cancer Letters CrossRef
3. Exploiting ING2 Epigenetic Modulation as a Therapeutic Opportunity for Non-Small Cell Lung Cancer
   Alice Blondel et al, 2019, Cancers CrossRef
4. Nuclear localization of ING3 is required to suppress melanoma cell migration, invasion and angiogenesis
   Ruiyao Zhou et al, 2020, Biochemical and Biophysical Research Communications CrossRef
5. In silico analysis prediction of HepTH1-5 as a potential therapeutic agent by targeting tumour suppressor protein networks
   Wan-Atirah Azemin et al, 2023, Journal of Biomolecular Structure and Dynamics CrossRef
6. ING2-WTAP is a potential therapeutic target in non-small cell lung cancer
   Hao Cheng et al, 2022, Biochemical and Biophysical Research Communications CrossRef
7. Inhibitor of Growth Factors Regulate Cellular Senescence
   Soudeh Ghafouri-Fard et al, 2022, Cancers CrossRef
8. Tumor-promoting properties of miR-8084 in breast cancer through enhancing proliferation, suppressing apoptosis and inducing epithelial–mesenchymal transition
   Yujing Gao et al, 2018, Journal of Translational Medicine CrossRef
9. Focus-ING on DNA Integrity: Implication of ING Proteins in Cell Cycle Regulation and DNA Repair Modulation
   Jérôme Archambeau et al, 2019, Cancers CrossRef
10. Up-regulated MiR-27-3p promotes the G1-S phase transition by targeting inhibitor of growth family member 5 in osteosarcoma
    Pei Ye et al, 2018, Biomedicine & Pharmacotherapy CrossRef
11. Why MUC16 mutations lead to a better prognosis: A study based on The Cancer Genome Atlas gastric cancer cohort
    Yu-Jie Huang et al, 2021, World Journal of Clinical Cases CrossRef